# Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

> **NCT03770416** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 18 (actual)

## Conditions studied

- Central Nervous System B-Cell Non-Hodgkin Lymphoma
- Recurrent Central Nervous System Lymphoma
- Refractory Central Nervous System Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03770416
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-15
- **Primary completion:** 2025-02-10
- **Final completion:** 2025-02-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03770416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03770416, "Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03770416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*